Sapigen Biologix, Technology Development Board collaborate for malaria, COVID nasal vaccine
New Delhi: The Technology Development Board (TDB) of the Union Ministry of Science and Technology and Sapigen Biologix Private Limited, Hyderabad on Saturday entered into an agreement for development and commercialisation of two novel vaccines -- ''Intranasal COVID-19 Vaccine and RTS, S Malaria Vaccine''.
Sapigen Biologix is helmed by Krishna Ella of Bharat Biotech Ltd, which developed Covaxin in collaboration with the ICMR.
Under the agreement, TDB and Bharat Biotech have pledged support of Rs 200 crore each to create a continuous corpus of Rs 400 crore for development and commercialisation of two novel vaccines -- intranasal COVID-19 Vaccine and ''RTS, S Malaria Vaccine'', Sapigen Biologix said in a statement.
The company aims to set up a state-of-the art cGMP facility in Bhubaneswar, in compliance with latest global standards, for manufacturing Intranasal COVID vaccine and (RTS, S) malaria vaccine initially and later expand the product portfolio by adding other vaccines.
Read also: Aster DM Healthcare to invest Rs 500 crore to provide healthcare at affordable cost in Tamil Nadu
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.